MedTrace Logo

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-04-16

Study results available
· View outcomes & findings →

Summary

This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.

Conditions

  • Smoking Cessation

Interventions

DRUG

SBP-9330

SBP-9330 oral capsules

DRUG

Placebo

Placebo oral capsules

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Sanford Burnham Prebys

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • Camino Pharma, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2023-03-06
Completion
2023-03-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948827 on ClinicalTrials.gov